Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial.
Wainwright CE, Vidmar S, Anderson V, Bourgeat P, Byrnes C, Carlin JB, Cheney J, Cooper P, Davidson A, Gailer N, Grayson-Collins J, Quittner A, Robertson C, Salvado O, Zannino D, Armstrong FD; ACFBAL; CF-GAIN Study Groups. Wainwright CE, et al. Among authors: byrnes c. Lancet Respir Med. 2024 Sep;12(9):703-713. doi: 10.1016/S2213-2600(24)00170-X. Epub 2024 Jun 5. Lancet Respir Med. 2024. PMID: 38851197 Clinical Trial.
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
Stick SM, Foti A, Ware RS, Tiddens HAWM, Clements BS, Armstrong DS, Selvadurai H, Tai A, Cooper PJ, Byrnes CA, Belessis Y, Wainwright C, Jaffe A, Robinson P, Saiman L, Sly PD; COMBAT CF Study Group. Stick SM, et al. Among authors: byrnes ca. Lancet Respir Med. 2022 Aug;10(8):776-784. doi: 10.1016/S2213-2600(22)00165-5. Epub 2022 Jun 2. Lancet Respir Med. 2022. PMID: 35662406 Clinical Trial.
Safety of bronchoalveolar lavage in young children with cystic fibrosis.
Wainwright CE, Grimwood K, Carlin JB, Vidmar S, Cooper PJ, Francis PW, Byrnes CA, Whitehead BF, Martin AJ, Robertson IF, Cooper DM, Dakin CJ, Masters IB, Massie RJ, Robinson PJ, Ranganathan S, Armstrong DS, Patterson LK, Robertson CF. Wainwright CE, et al. Pediatr Pulmonol. 2008 Oct;43(10):965-72. doi: 10.1002/ppul.20885. Pediatr Pulmonol. 2008. PMID: 18780333
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.
Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Rosenfeld M, Tiddens HA, Wainwright CE; ACFBAL Study Investigators. Byrnes CA, et al. Thorax. 2013 Jul;68(7):643-51. doi: 10.1136/thoraxjnl-2012-202342. Epub 2013 Jan 23. Thorax. 2013. PMID: 23345574 Free PMC article. Clinical Trial.
Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis.
Moodie M, Lal A, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Robertson CF, Tiddens HA, Wainwright CE; Australasian Cystic Fibrosis Bronchoalveolar Lavage Study Investigators. Moodie M, et al. J Pediatr. 2014 Sep;165(3):564-569.e5. doi: 10.1016/j.jpeds.2014.05.031. Epub 2014 Jul 1. J Pediatr. 2014. PMID: 24996984 Clinical Trial.
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort.
Wijker NE, Vidmar S, Grimwood K, Sly PD, Byrnes CA, Carlin JB, Cooper PJ, Robertson CF, Massie RJ, Kemner van de Corput MPC, Cheney J, Tiddens HAWM, Wainwright CE; Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) and Follow-up of the ACFBAL (CF-FAB) study groups; following investigators constitute the ACFBAL Study Investigators Group:; following investigators constitute the CF FAB Study Investigators Group:; Additional contributions: We are indebted to all current and former clinical and research staff from Queensland Children's Hospital, Brisbane:. Wijker NE, et al. Among authors: byrnes ca. Eur Respir J. 2020 Apr 3;55(4):1901694. doi: 10.1183/13993003.01694-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 31949117 Free article.
Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, Tjhung I, Hare KM, Ware RS, Chang AB. Valery PC, et al. Among authors: byrnes ca. Lancet Respir Med. 2013 Oct;1(8):610-620. doi: 10.1016/S2213-2600(13)70185-1. Epub 2013 Sep 17. Lancet Respir Med. 2013. PMID: 24461664 Clinical Trial.
194 results